Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being

Recruiting

• Conditions: Chronic Pulmonary Aspergillosis

• Registration Number: NCT06885905
• Lead Sponsor: Imperial College London

Brief Summary

To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-11-27
• Status Verified: 2025-03
• Study First Submitted: 2025-03-13
• Study First Submitted QC: 2025-03-13
• Last Update Submitted: 2025-03-13
• Study First Posted: 2025-03-20
• Last Update Posted: 2025-03-20
• Primary Completion: 2025-08-23
• Study Completion: 2026-04-23

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. All patients >/= 18 years old and able to provide informed consent
2. Patients with a diagnosis of chronic pulmonary aspergillosis
3. To speak and understand English
4. Able to provide informed consent

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.	30 months	To develop and validate a novel disease-specific health-related quality of life (HRQoL) measure in chronic pulmonary aspergillosis (CPA): The Chronic Pulmonary Aspergillosis Health Assessment Questionnaire (CPA-HAQ)

Secondary Outcome Measures

Name	Time	Method
Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.	30 months	Correlating how HRQoL outcomes relate to existing disease prognostic markers.

Trial Locations

Locations (3)

Ninewells Hospital & Medical School; 🇬🇧 Dundee, United Kingdom

Imperial College London; 🇬🇧 London, United Kingdom

Manchester NHS Foundation Trust; 🇬🇧 Manchester, United Kingdom